1.28
29.06%
0.2898
After Hours:
1.25
-0.03
-2.34%
Why is Jaguar Health Inc (JAGX) Stock down?
We've noticed a 5.17% decline in Jaguar Health Inc (JAGX) stock during the 2024-12-02 trading session. While this could be attributed to normal volatility or various internal and external factors, please be aware that we are actively monitoring the situation, and we'll provide timely updates as soon as possible!
21 Nov, 2023:
Jaguar Health Inc Stock (JAGX) dropped by 24.81% from $0.462 to $0.3474 in the trading on Tuesday November 21, 2023. The reason why JAGX stock down today is due to the update on Phase 3 trial for plant-based drug. Jaguar Health announced that its subsidiary, Napo Pharmaceuticals, is yet to receive topline results from its OnTarget Phase 3 trial for the plant-based drug Crofelemer. This pivotal study aims to assess Crofelemer's efficacy as a preventive treatment for cancer therapy-related diarrhea in adults. While topline results are expected soon, Jaguar Health (JAGX) refrained from providing a specific timeline.
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):